🌐Read in
മലയാളം தமிழ் मराठी বাংলা ಕನ್ನಡ తెలుగు ગુજરાતી ਪੰਜਾਬੀ हिन्दी

Natco Pharma Ltd: ₹15,899 Crore Niche Pharma Sniper with a Patent for Profits

1. At a Glance

Natco Pharma isn’t a “make 500 drugs, hope something sticks” company. It’s a precision striker — targeting niche, complex generics and first-to-file opportunities. Market cap ₹15,899 Cr, CMP ₹888, and a deliciously low P/E of 9.38. Q1 FY26 revenue was ₹1,390.6 Cr with PAT ₹480.3 Cr — margins fat enough to make competitors choke. Debt? Almost gone. ROCE? A sizzling 32.8%.

2. Introduction

Founded in 1981, Natco has built a business model around being the guy who walks in late to the party but leaves with the best dessert. They specialise in para-IV filings, high-barrier generics, oncology drugs, and niche APIs — letting Big Pharma spend billions developing products, then swooping in with cost-efficient versions when the patents expire (or when they win a legal battle).

This strategy has delivered 33.4% PAT CAGR over the past five years. The stock, however, is sulking — down ~41% in the last year thanks to volatile US sales and quarterly hiccups.

3. Business Model (WTF Do They Even Do?)

  • Finished Dosage Formulations (FDF) – Key market is the US with partners like Teva, Mylan, Sun, Alvogen; now expanding in MENA, LATAM, and SEA.
  • Active Pharmaceutical Ingredients (APIs) – Backward integration to protect margins.
  • Contract Manufacturing – High-value niche manufacturing for other pharma companies.

The beauty? Targeting low-competition, complex drugs — avoiding the race-to-zero pricing in commoditised generics.

4. Financials Overview

  • TTM Revenue: ₹4,396 Cr
  • TTM EBITDA: ₹1,962 Cr (EBITDA margin ~45%)
  • TTM PAT: ₹1,695 Cr (Net margin ~38.6%)
  • Q1 FY26 Revenue: ₹1,390.6 Cr (+6% YoY)
  • Q1 FY26 PAT: ₹480.3 Cr (-28% YoY due to high base effect)

P/E Recalculation:
Q1 EPS = ₹26.84 ⇒ Annualised EPS ≈ ₹107.4
CMP ₹888 ⇒ Adjusted P/E ≈ 8.27 — screaming undervaluation for a high-margin, debt-light pharma company.

5. Valuation (Fair Value Range)

MethodCalculationFV (₹)
P/E MethodEPS ₹100–107 × P/E 10–121,000–1,280
EV/EBITDAEBITDA ₹1,962 Cr × 9–10 EV/EBITDA – Net Debt ₹(Negative)980–1,100
DCF (10% WACC, 4% growth)Based on 5-year conservative projections950–1,150

Fair Value Range: ₹950 – ₹1,150

This FV range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

  • Interim Dividend – ₹2/share declared for FY26.
  • US pipeline – New launches in
Read Full Article Here
Become a member

Leave a Reply

FII & DII Data | Institutional Money Tracker

FII & DII Data

Institutional Money Flow Tracker | by Mr. Chartist
LOCAL ARCHIVE (Mar 13)
Latest Trading Session
Friday, 13 March 2026
Aggressive Selling
FII / FPI NET
-₹10,724 Cr
DII NET
+₹9,977 Cr
FII Aggression: 52% DII Support: 48%
Combined Liquidity -₹747 Cr
Current FII Streak
—
Streak Volume
—
5-Day FII Net Velocity
—
Computing…
FII 5-Yr Cumulative
-₹11.01L Cr
Historical allocation extraction
DII 5-Yr Cumulative
+₹20.45L Cr
The domestic fortress
SIP Monthly Run-Rate
₹26,500 Cr
Retail structural backbone
FII NSE500 Ownership
16.1%
Down from 28% peak

Derivatives Positioning (F&O)

Participant-wise Open Interest Analysis
—
FOREIGN INSTITUTIONAL INVESTORS (FII)
Index Futures
Long: — Short: —
Stock Futures
Long: — Short: —
Index Calls
Long: — Short: —
Index Puts
Long: — Short: —
DOMESTIC INSTITUTIONAL INVESTORS (DII)
Index Futures
Long: — Short: —
Stock Futures
Long: — Short: —
Note: DIIs primarily use Index Futures for hedging; options writing is limited compared to FIIs.
Data Matrices
Flow Heatmaps
Historical Charts
Documentation
FII 45-Day Flow Matrix
Visualizing sell-off density
Extreme Sell
Heavy Buy
DII 45-Day Flow Matrix
Domestic absorption pattern
Light Activity
Heavy Accumulation
Daily (Last 15)
Weekly (12W)
Monthly (24M)
Annual Tracker
Trading Date FII Gross Buy FII Gross Sell FII Net DII Gross Buy DII Gross Sell DII Net Total Liquidity
Week Ending FII Net DII Net Combined Liquidity Weekly Signal
Month & Year FII Net DII Net Net Money Flow Nifty Change
Calendar Year FII Equities Net DII Equities Net Total Flow DII Multiplier
Monthly Net Flows (Last 12m)
₹ Crore flows visualization
Multi-Year Cumulative Divergence
FII Extraction vs DII Injection
📊
FII & DII Data — User Manual
A fully open-source, institutional-grade terminal to track FII & DII flows in Indian equity markets.
Built by @Mr_Chartist — free for everyone to use, fork, and share.
✓ LIVE NSE SYNC ✓ 14-YEAR ARCHIVE ✓ MOBILE RESPONSIVE ✓ OPEN SOURCE
1
Live Sync Engine & Status

The terminal automatically fetches latest FII & DII data from NSE India on page load via CORS proxy integration, ensuring you always have access to the most current institutional flow data.

LIVE SYNC — Today's session data fetched successfully
LOCAL ARCHIVE — Using embedded historical data
🌐 Open Source — Use It, Fork It, Share It

This tool is completely free and open. No backend, no login, no subscription. Just open the HTML file and you have institutional-grade FII & DII analytics in your browser.

Follow @Mr_Chartist 📊 Version 6.0 — March 2026
error: Content is protected !!